Similar Items: First-Line Serplulimab versus Other Anti-PD-1/PD-L1 Antibodies Plus Chemotherapy for Esophageal Squamous Cell Carcinoma: A Systematic Review with Benefit-Risk Assessment via Matching-Adjusted Indirect Comparison
- Evaluation of plant-expressed human PD-1 as an immunogen capable of inducing native PD-1 recognizing antibodies
- Biomarker‐based long‐term safety and efficacy of PD‐1/PD‐L1 inhibitors combined with chemotherapy in advanced gastroesophageal carcinomas: A systematic review and meta‐analysis
- PD-L1 Expression and Its Association With p16 in Head and Neck Squamous Cell Carcinoma in Southwestern Uganda
- Oncolytic virus and PD-1/PD-L1 blockade combination therapy
- Prognostic Value of UBE2S, HIF-1α, and FOXM1 Expression in Esophageal Squamous Cell Carcinoma
- Investigation into hardness changes of Pd 11.1 at.% Cu and Pd 11.1 at .% Nb after heat treatments